Compare Gilead Sciences, Inc. (GILD) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Bitcoin Trust — how do they compare? Gilead Sciences, Inc. trades at $133.4 (market cap $163.51B), while iShares Bitcoin Trust trades at $36.61. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares Bitcoin Trust pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| GILD | IBIT | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Crypto-linked |
52-Week High | $155.80 | $71.29 |
52-Week Low | $108.22 | $33.29 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
IBIT trades at $36.305, down 0.75% on the day, with technical indicators showing a mixed but overall bullish signal. The stock is testing key resistance levels near $37 while maintaining support at $36. Recent news highlights IBIT's position as the largest Bitcoin ETF with $44.9 billion in assets under management, though the broader Bitcoin ETF sector has experienced significant outflows totaling $4.5 billion in June 2026 according to Zacks Investment Research.
The outlook remains cautiously optimistic with strong institutional backing but faces headwinds from cryptocurrency market volatility. Key investment opportunities include IBIT's market leadership position and growing ETF adoption, while risks center on Bitcoin price fluctuations and competitive pressures from alternative crypto exposure vehicles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
